Drug intelligence / Profile preview

Ketograce DS

Development stage: Unknown
Lead developer: Biokindle Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Ketograce DS is a nutritional supplement developed by Biokindle Lifesciences for the management of chronic kidney disease (CKD). It contains alpha-ketoanalogues of essential amino acids, which are nitrogen-free analogues of amino acids provided in the form of calcium salts. The supplement is designed to be used in conjunction with a low-protein or very low-protein diet, particularly in patients with a glomerular filtration rate (GFR) below 25 ml/min. By providing essential amino acids without the associated nitrogen load, Ketograce DS helps improve protein metabolism and reduce the production of uremic toxins like urea. This mechanism helps delay the progression of renal failure and the subsequent need for long-term dialysis.

Brand names: Ketograce DSKETO&GRACE DS
Other names: alpha-ketoanalogue

Beyond the preview

Go deeper on Ketograce DS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ketograce DS.

Explore the full profile